Publications by authors named "Remedios Castello"

Claim this Profile
P
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and endometriosis. Influence of PAI-1 polymorphism on PAI-1 antigen and mRNA expression.
Luis A Ramón, Juan Gilabert-Estellés, Raul Cosín, Juan Gilabert, Francisco España

Thromb Res· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism.
Eva Solá, Amparo Vayá, Francisco España, Remedios Castelló, Luis A Ramón

Thromb Res· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
José M Ricart, Luis A Ramón, Amparo Vayá, Francisco España, Maria-Luisa Santaolaria

Br J Haematol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Remedios Castelló, Jose M Landete, Francisco España, Carlos Vázquez, Carlos Fuster

Thromb Res· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism.
Gregory Bix, Remedios Castello, Michelle Burrows, Jason J Zoeller, Michelle Weech

J Natl Cancer Inst· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Remedios Castelló, Francisco España, Carlos Vázquez, Carlos Fuster, Sergio M Almenar

Thromb Res· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein (a) in young individuals as a marker of the presence of ischemic heart disease and the severity of coronary lesions.
Esther Zorio, Cristina Falco, Miguel A Arnau, Francisco España, Ana Osa, Remedios Castello

Haematologica· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasminogen activators and plasminogen activator inhibitors in endometriosis.
Juan Gilabert-Estelles, Remedios Castello, Juan Gilabert, Luis Andres Ramon, Francisco Espana

Front Biosci· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
Esther Zorio, Remedios Castelló, Cristina Falcó, Francisco España, Ana Osa

Br J Haematol· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
Remedios Castelló, Amparo Estellés, Carlos Vázquez, Cristina Falcó, Francisco España

Clin Chem· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis